Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 4 complete abstracts (583 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
Substances that stimulate mitosis and lymphocyte transformation. They include not only substances associated with lectins, but also substances from streptococci (associated with streptolysin S) and from strains of alpha-toxin-producing staphylococci. (Stedman, 25th ed)
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: Mitogen; Phytomitogens; Phytomitogen.
Where it fits in the MeSH classification
- Broader topics
- Mitosis Modulators
- See also
- Receptors, Mitogen
Related concepts
- Lectins
Research landscape
PubMed indexes 11,648 records tagged with the MeSH heading “Mitogens” (counts retrieved 2026-10-29). 180 of them (1.5%) were published from 2020 onward, and the busiest period so far is through 1999 with 8,843 records.
Reviews account for 663 records (5.7%) and meta-analyses for 0. Randomized controlled trials number 49 (0.4%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.
Show the data
| Period | Records |
|---|---|
| through 1999 | 8,843 |
| 2000-2009 | 2,011 |
| 2010-2019 | 614 |
| 2020 onward | 180 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 663 | 5.7% |
| Meta-analyses | 0 | 0.0% |
| Randomized controlled trials | 49 | 0.4% |
Method: PubMed query "Mitogens"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.
Reading the evidence in pharmacology
Drug evidence builds in layers: laboratory pharmacology describes how a compound acts, pharmacokinetic studies describe how the body handles it, and randomized trials test whether it helps and what harms it causes. Post-marketing surveillance and observational studies reveal rarer adverse effects but cannot prove causation. This page is educational and is not a recommendation to start, stop or change any medicine; decisions about treatment belong with a qualified clinician.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
| Study / authors | Year | Source label / design | Europe PMC citations | Licence / source |
|---|---|---|---|---|
| Nrg1 is an injury-induced cardiomyocyte mitogen for the endogenous heart regeneration program in zebrafish | 2015 | Research article Design not recorded in structured metadata | 257 | cc by PMID 25830562 · DOI · PMC4379493 |
| Competition for Mitogens Regulates Spermatogenic Stem Cell Homeostasis in an Open Niche | 2019 | Research article Design not recorded in structured metadata | 137 | cc by PMID 30581080 · DOI · PMC6327111 |
| High mitogenic stimulation arrests angiogenesis | 2019 | Research article Design not recorded in structured metadata | 111 | cc by PMID 31043605 · DOI · PMC6494832 |
| Transient proliferation by reversible YAP and mitogen control of the cyclin D1/p27 ratio | 2026 | Research article Design not recorded in structured metadata | 3 | cc by PMID 41611993 · DOI · PMC12957376 |
Nrg1 is an injury-induced cardiomyocyte mitogen for the endogenous heart regeneration program in zebrafish [1]
Abstract reading summary — source excerpts
- Opening excerpt
- Heart regeneration is limited in adult mammals but occurs naturally in adult zebrafish through the activation of cardiomyocyte division.
- Closing excerpt
- Our findings identify Nrg1 as a potent, induced mitogen for the endogenous adult heart regeneration program.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (141 words)
Heart regeneration is limited in adult mammals but occurs naturally in adult zebrafish through the activation of cardiomyocyte division. Several components of the cardiac injury microenvironment have been identified, yet no factor on its own is known to stimulate overt myocardial hyperplasia in a mature, uninjured animal. In this study, we find evidence that Neuregulin1 (Nrg1), previously shown to have mitogenic effects on mammalian cardiomyocytes, is sharply induced in perivascular cells after injury to the adult zebrafish heart. Inhibition of Erbb2, an Nrg1 co-receptor, disrupts cardiomyocyte proliferation in response to injury, whereas myocardial Nrg1 overexpression enhances this proliferation. In uninjured zebrafish, the reactivation of Nrg1 expression induces cardiomyocyte dedifferentiation, overt muscle hyperplasia, epicardial activation, increased vascularization, and causes cardiomegaly through persistent addition of wall myocardium. Our findings identify Nrg1 as a potent, induced mitogen for the endogenous adult heart regeneration program.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 25830562 · DOI · PMC4379493
Competition for Mitogens Regulates Spermatogenic Stem Cell Homeostasis in an Open Niche [2]
Abstract reading summary — source excerpts
- Opening excerpt
- In many tissues, homeostasis is maintained by physical contact between stem cells and an anatomically defined niche.
- Closing excerpt
- We propose that this model provides a generic and robust mechanism to support stem cell homeostasis in open, or facultative, niche environments.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (151 words)
In many tissues, homeostasis is maintained by physical contact between stem cells and an anatomically defined niche. However, how stem cell homeostasis is achieved in environments where cells are motile and dispersed among their progeny remains unknown. Using murine spermatogenesis as a model, we find that spermatogenic stem cell density is tightly regulated by the supply of fibroblast growth factors (FGFs) from lymphatic endothelial cells. We propose that stem cell homeostasis is achieved through competition for a limited supply of FGFs. We show that the quantitative dependence of stem cell density on FGF dosage, the biased localization of stem cells toward FGF sources, and stem cell dynamics during regeneration following injury can all be predicted and explained within the framework of a minimal theoretical model based on "mitogen competition." We propose that this model provides a generic and robust mechanism to support stem cell homeostasis in open, or facultative, niche environments.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 30581080 · DOI · PMC6327111
High mitogenic stimulation arrests angiogenesis [3]
Abstract reading summary — source excerpts
- Opening excerpt
- Appropriate therapeutic modulation of endothelial proliferation and sprouting is essential for the effective inhibition of angiogenesis in cancer or its induction in cardiovascular disease.
- Closing excerpt
- The identified mechanism should be considered to achieve optimal therapeutic modulation of angiogenesis.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (141 words)
Appropriate therapeutic modulation of endothelial proliferation and sprouting is essential for the effective inhibition of angiogenesis in cancer or its induction in cardiovascular disease. The current view is that an increase in growth factor concentration, and the resulting mitogenic activity, increases both endothelial proliferation and sprouting. Here, we modulate mitogenic stimuli in different vascular contexts by interfering with the function of the VEGF and Notch signalling pathways at high spatiotemporal resolution in vivo. Contrary to the prevailing view, our results indicate that high mitogenic stimulation induced by VEGF, or Notch inhibition, arrests the proliferation of angiogenic vessels. This is due to the existence of a bell-shaped dose-response to VEGF and MAPK activity that is counteracted by Notch and p21, determining whether endothelial cells sprout, proliferate, or become quiescent. The identified mechanism should be considered to achieve optimal therapeutic modulation of angiogenesis.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 31043605 · DOI · PMC6494832
Transient proliferation by reversible YAP and mitogen control of the cyclin D1/p27 ratio [4]
Abstract reading summary — source excerpts
- Opening excerpt
- Hippo-YAP signaling orchestrates transient proliferation during tissue repair and is therefore an attractive target in regenerative medicine.
- Closing excerpt
- Thus, critical for regeneration without cancer initiation, robust proliferation responses result from a YAP-induced and receptor-mediated prolonged increase in the cyclin D1/p27 ratio, which is reversed by delayed suppression of receptor signaling after contact inhibition of YAP.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (150 words)
Hippo-YAP signaling orchestrates transient proliferation during tissue repair and is therefore an attractive target in regenerative medicine. However, it is unclear how YAP integrates mitogen and contact signals to start and stop proliferation. Here we show that reduced contact inhibition, increased mitogen signaling, and YAP-TEAD activation converge on increasing the nuclear cyclin D1/p27 protein ratio during early G1 phase, towards a threshold ratio that dictates whether individual cells enter or exit the cell cycle. YAP increases this ratio in concert with inducing mitogen signaling, by increasing EGFR and other receptors that signal primarily through ERK. After a delay, contact inhibition suppresses YAP activity, which gradually downregulates mitogen signaling and the cyclin D1/p27 ratio. Thus, critical for regeneration without cancer initiation, robust proliferation responses result from a YAP-induced and receptor-mediated prolonged increase in the cyclin D1/p27 ratio, which is reversed by delayed suppression of receptor signaling after contact inhibition of YAP.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41611993 · DOI · PMC12957376
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article Early signals in the mitogenic response [5]
- Research article MAPKs: new JNK expands the group [6]
- Research article Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts [7]
- Research article Too many rodent carcinogens: mitogenesis increases mutagenesis [8]
- Research article Mitogen and stress response pathways: MAP kinase cascades and phosphatase regulation in mammals and yeast [9]
- Research article Morphogen to mitogen: the multiple roles of hedgehog signalling in vertebrate neural development [10]
References
- Gemberling M, Karra R, Dickson AL, Poss KD. Nrg1 is an injury-induced cardiomyocyte mitogen for the endogenous heart regeneration program in zebrafish. . 2015. PMID 25830562 · DOI · PMC4379493
- Kitadate Y, Jörg DJ, Tokue M, Maruyama A, Ichikawa R, Tsuchiya S, et al.. Competition for Mitogens Regulates Spermatogenic Stem Cell Homeostasis in an Open Niche. . 2019. PMID 30581080 · DOI · PMC6327111
- Pontes-Quero S, Fernández-Chacón M, Luo W, Lunella FF, Casquero-Garcia V, Garcia-Gonzalez I, et al.. High mitogenic stimulation arrests angiogenesis. . 2019. PMID 31043605 · DOI · PMC6494832
- Ferrick KR, Upadhya SW, Fan Y, Ratnayeke N, Teruel MN, Meyer T. Transient proliferation by reversible YAP and mitogen control of the cyclin D1/p27 ratio. . 2026. PMID 41611993 · DOI · PMC12957376
- Rozengurt E. Early signals in the mitogenic response. Science. 1986. PMID 3018928 · DOI
- Davis RJ. MAPKs: new JNK expands the group. Trends Biochem Sci. 1994. PMID 7855889 · DOI
- Grotendorst GR. Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev. 1997. PMID 9462483 · DOI
- Ames BN, Gold LS. Too many rodent carcinogens: mitogenesis increases mutagenesis. Science. 1990. PMID 2136249 · DOI
- Waskiewicz AJ, Cooper JA. Mitogen and stress response pathways: MAP kinase cascades and phosphatase regulation in mammals and yeast. Curr Opin Cell Biol. 1995. PMID 8608010 · DOI
- Fuccillo M, Joyner AL, Fishell G. Morphogen to mitogen: the multiple roles of hedgehog signalling in vertebrate neural development. Nat Rev Neurosci. 2006. PMID 16988653 · DOI
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-10-29.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.